1,088 results on '"Schnittger, S"'
Search Results
2. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes
3. Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1
4. Subtype-specific patterns of molecular mutations in acute myeloid leukemia
5. Correction: Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1
6. Age, not therapy intensity, determines outcomes of adults with acute myeloid leukemia
7. Increasing intensity of therapies assigned at diagnosis does not improve survival of adults with acute myeloid leukemia
8. Next-generation deep-sequencing detects multiple clones of CALR mutations in patients with BCR-ABL1 negative MPN
9. Array-based comparative genomic hybridization detects copy number variations with prognostic relevance in 80% of ALL with normal karyotype or failed chromosome analysis
10. Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V+ advanced systemic mastocytosis
11. Rare FLT3 deletion mutants may provide additional treatment options to patients with AML: an approach to individualized medicine
12. Correction: Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1 (Leukemia, (2019), 33, 8, (1910-1922), 10.1038/s41375-019-0413-0)
13. FLT3 Length Mutations and MLL-Duplications in AML: Correlation to Cytogenetics, FAB-Subtype,and Prognosis
14. Different Mechanisms Lead to Rearrangements of the MLL Gene in Cases with Acute Myeloid Leukemia (AML) and Translocation t(10;l1)
15. RT-PCR in Diagnostics and Monitoring of Acute Myeloid
16. MLL-Duplications are Rare and Associated with Poor Prognosis in Acute Myeloid Leukemia
17. Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event
18. WT1 mutations are secondary events in AML, show varying frequencies and impact on prognosis between genetic subgroups
19. Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status
20. Array CGH identifies copy number changes in 11% of 520 MDS patients with normal karyotype and uncovers prognostically relevant deletions
21. Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib
22. High number of additional genetic lesions in acute myeloid leukemia with t(8;21)/RUNX1-RUNX1T1: frequency and impact on clinical outcome
23. The role of different genetic subtypes of CEBPA mutated AML
24. SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients
25. Monitoring of residual disease by next-generation deep-sequencing of RUNX1 mutations can identify acute myeloid leukemia patients with resistant disease
26. Long-term outcome of patients with newly diagnosed chronic myeloid leukemia: a randomized comparison of stem cell transplantation with drug treatment
27. Prognostic impact and landscape of NOTCH1 mutations in chronic lymphocytic leukemia (CLL): a study on 852 patients
28. SOX11 overexpression is a specific marker for mantle cell lymphoma and correlates with t(11;14) translocation, CCND1 expression and an adverse prognosis
29. Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1
30. LB738 Anti-inflammatory activity of traditionally used, bioactive mushrooms in skin
31. Age, JAK2V617F and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis
32. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations
33. Acute erythroid leukemia (AEL) can be separated into distinct prognostic subsets based on cytogenetic and molecular genetic characteristics
34. High incidence of RAS signalling pathway mutations in MLL-rearranged acute myeloid leukemia
35. Landmark analysis of DNMT3A mutations in hematological malignancies
36. A novel recurrent AML1–ETO fusion: tight in vivo association with BCR–ABL1
37. Molecular mutations are prognostically relevant in AML with intermediate risk cytogenetics and aberrant karyotype
38. GATA2 mutations are frequent in intermediate-risk karyotype AML with biallelic CEBPA mutations and are associated with favorable prognosis
39. A rare but specific subset of adult AML patients can be defined by the cytogenetically cryptic NUP98–NSD1 fusion gene
40. ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome
41. Moderne Diagnostik bei akuten und chronischen Leukämien
42. Diagnostik akuter Leukämien: Interaktion phänotypischer und genetischer Methoden
43. Landscape of TET2 mutations in acute myeloid leukemia
44. Deletion of the tumor-suppressor gene NF1 occurs in 5% of myeloid malignancies and is accompanied by a mutation in the remaining allele in half of the cases
45. Low rate of calreticulin mutations in refractory anaemia with ring sideroblasts and marked thrombocytosis
46. Prognosis in patients with MDS or AML and bone marrow blasts between 10% and 30% is not associated with blast counts but depends on cytogenetic and molecular genetic characteristics
47. Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia
48. Development of standardized approaches to reporting of minimal residual disease data using a reporting software package designed within the European LeukemiaNet
49. The inv(3)(q21q26)/t(3;3)(q21;q26) is frequently accompanied by alterations of the RUNX1, KRAS and NRAS and NF1 genes and mediates adverse prognosis both in MDS and in AML: a study in 39 cases of MDS or AML
50. Characterization of NPM1-mutated AML with a history of myelodysplastic syndromes or myeloproliferative neoplasms
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.